Skip to content

Search

Evaluating the genetic contribution to rheumatic heart disease pathogenesis in Australian Aboriginal and Torres Strait Islander communities

We are conducting a genetic study to better understand why some people are susceptible to RHD and others are not.

Establishing a Western Australian Congenital and Acquired Heart Disease Database

The main objective of the study is to establish a comprehensive register of congenital and acquired heart disease in WA with accurate re-classification of all cases through Princess Margart Hospital using international diagnostic codes.

Development of a longer acting formulation of Penicillin G for the treatment and prevention of acute rheumatic fever and rheumatic heart disease

This project aims to develop a longer acting formulation of penicillin, such that frequency of the injection can be increased up to 3-6 months.

BPG Formulation Preferences Study: Exploring patient, family and clinician reformulations preferences for BPG

The key objective of this study is to collect data about patient and clinician preferences about reformulations.

Australian Strep A Vaccine Initiative (ASAVI)

The Australian Strep A Vaccine Initiative (ASAVI) is an Australian-led global initiative with the goal of reducing the disease burden caused by Group A Streptococcus (Strep A) infection through effective vaccination.

Interventions to eliminate rheumatic heart disease

Funded by a 5-year NHMRC Investigator grant to implement a strategy to eliminate rheumatic heart disease (RHD) as a public health problem in Australia.

RHD Screening Program - GE Healthcare

This project aims to empower local clinicians with skills and knowledge of using handheld echocardiography (HAND) that will allow for mobile service provision into remote Indigenous communities.

Head-to-head Pharmacokinetic Comparison of Bicillin ® L-A versus Lyophilised (Powdered) Benzathine Penicillin G administered by the Intramuscular and Subcutaneous Routes

Fiji has one of the highest burdens of RHD is in the world and RHD is the second most common cause of death in young people in Fiji.

Otitis media at 6-monthly assessments of Australian First Nations children between ages 12–36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines

In remote communities of northern Australia, First Nations children with hearing loss are disproportionately at risk of poor school readiness and performance compared to their peers with no hearing loss. The aim of this trial is to prevent early childhood persisting otitis media (OM), associated hearing loss and developmental delay.

Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials

Australian First Nations children are at very high risk of early, recurrent, and persistent bacterial otitis media and respiratory tract infection. With the PREVIX randomised controlled trials, we aimed to evaluate the immunogenicity of novel pneumococcal conjugate vaccine (PCV) schedules.